Skip to main content

Everything You Need to Know About Lupkynis for SLE

Lupus nephritis (LN) is a serious and potentially life-threatening complication of systemic lupus erythematosus (SLE) — a chronic autoimmune disease in which the immune system mistakenly attacks the body’s own tissues. In Lupus Nephritis, this attack specifically targets the kidneys, causing inflammation and damaging nephrons- the structures that filter waste from the blood. If left untreated, lupus nephritis can lead to progressive kidney damage, high blood pressure, proteinuria (protein in the urine), chronic kidney disease, and eventually kidney failure.1 

 

Symptoms and Diagnosis: 2 

  • Swollen hands, feet or face. 

  • Foamy urine due to proteinuria. 

  • Fatigue and elevated blood pressure. 

  • Weight gain from fatigue and fluid retention.  

  • Decreased urine output. 

Kidney Biopsy remains the gold standard for LN diagnosis, apart from a kidney biopsy other imaging and lab tests are done to rule out other diseases & assess the extent of the disease. 

Management of Lupus Nephritis: 

Managing lupus nephritis requires early intervention and effective treatment to preserve kidney function and improve long-term outcomes. Traditionally, therapies have included corticosteroids and immunosuppressive agents; however, these often come with significant side effects and inconsistent results. The introduction of Lupkynis (voclosporin) — a novel oral calcineurin inhibitor — represents a major advancement. Approved by the FDA in 2021, Lupkynis offers a targeted approach to managing active lupus nephritis with a better-defined dosing strategy and a more predictable pharmacologic profile.1 

Understanding the correct dosage, administration methods, monitoring requirements, and strategies for managing potential side effects is crucial for patients and healthcare providers to optimize outcomes with Lupkynis therapy. 

Dosage Guidelines 

Lupkynis is prescribed with a starting dosage of 23.7 mg twice daily (approximately 12 hours apart) on an empty stomach.1 Dosage adjustments are often based on individual patient response, kidney function, and blood levels of voclosporin. 

The goal is to maintain effective drug levels while minimizing potential toxicity. After initiating therapy, healthcare providers closely monitor patients and may adjust the dose accordingly. It's important to note that the maximum recommended dose is 44.8 mg twice daily. 1 

Additionally, Lupkynis must always be used in combination with background immunosuppressive therapy, typically including mycophenolate mofetil (MMF) and corticosteroids.3, 4 Lupkynis is not used as a standalone treatment. 

Administration Tips 

Proper administration ensures that Lupkynis works effectively while reducing the chance of adverse events. Here are key administration guidelines: 

  • Timing: Take Lupkynis approximately every 12 hours, at the same times each day to maintain steady levels in the bloodstream. 1 

  • Fasting: Lupkynis should be taken on an empty stomach, either one hour before or two hours after a meal. 1 

  • Swallow Whole: Capsules should be swallowed whole and not crushed, chewed, or split. 1 

  • Missed Dose: If a patient misses a dose and it’s close to the next scheduled dose, they should skip the missed dose and resume their regular schedule. Double dosing should be avoided. 1 

  • Avoid Grapefruit Products: Grapefruit can interfere with how the body processes voclosporin, potentially increasing the risk of side effects. 3 

Patients should also be aware of other medications and supplements they are taking because Lupkynis can interact with drugs metabolized by the CYP3A enzyme system, commonly affecting drug levels.3 

Monitoring During Treatment 

Monitoring is critical for patients on Lupkynis to ensure efficacy and detect any potential toxicity early. 

  • Kidney Function: Regular tests measuring serum creatinine and estimated glomerular filtration rate (eGFR) are crucial. Significant increases in serum creatinine may require dose adjustment or discontinuation.4 

  • Blood Pressure: Lupkynis can cause hypertension. Therefore, blood pressure should be monitored regularly, and antihypertensive therapy may be required.3 

  • Blood Sugar Levels: Since voclosporin can cause hyperglycemia, patients (especially those on corticosteroids) should have periodic blood sugar checks.4 

  • Electrolytes: Monitoring potassium and magnesium levels is recommended because of the risk of imbalances.4 

  • Infection Surveillance: As an immunosuppressant, Lupkynis can increase the risk of infections, so monitoring for signs of infection is essential throughout the course of treatment.4 

Typically, healthcare providers schedule frequent visits during the first few months and adjust the follow-up frequency based on the patient's stability and response. 

Managing Potential Side Effects 

While many patients tolerate Lupkynis well, some may experience side effects. Understanding these can help in managing them effectively. 

Common Side Effects: 4 

  • Increased blood pressure (hypertension) 

  • Decreased kidney function (seen as elevated serum creatinine)3 

  • Diarrhea 

  • Headache 

  • Anemia 

  • Cough 

Most side effects are manageable through dose adjustments or supportive treatments. 

Serious Side Effects 

  • Serious Infections: Patients must report symptoms like fever, chills, or cough immediately3 

  • Malignancies: Like other immunosuppressants, Lupkynis may increase the risk of certain cancers, particularly skin cancer and lymphomas4 

Patient Tips for Side Effect Management  

  • Stay Hydrated: To support kidney function and minimize the risk of elevated creatinine. 

  • Blood Pressure Monitoring at Home: Home BP monitors can help patients track their blood pressure regularly. 

  • Report New Symptoms Promptly: Any new symptom, even minor, should be shared with the healthcare provider. 

  • Protect Skin from the Sun: Use sunscreen and protective clothing to reduce the risk of skin cancers. 

  • Medication List Management: Keep an updated list of all medications and supplements to share with healthcare providers at every visit. 

Patients should also maintain open and regular communication with their healthcare team. Never stop or adjust the dose without professional advice. 

Lupkynis marks a major advancement in the management of lupus nephritis, offering hope to patients who previously had limited options. However, its successful use requires strict adherence to dosage and administration guidelines, vigilant monitoring, and proactive management of potential side effects. With good education and collaboration between patients and healthcare teams, Lupkynis can be an effective tool in preserving kidney function and improving quality of life for those with lupus nephritis. 

How Indian Patients Can Access Lupkynis: 

Indian patients can access Lupkynis through the Rx4U’s Named Patient Purchase (NPP) Program, a legal channel that allows the import of rare, specialty, or yet-to-be-approved treatments into India. This program ensures that patients can receive critical, globally-approved medications in a timely and regulated manner, offering new hope to those managing complex conditions like lupus nephritis. 

Given the limited availability of advanced treatment options locally, Lupkynis stands out as a major breakthrough for patients battling lupus-related kidney disease. Through the Rx4U NPP program, Indian patients can tap into the latest medical innovations that might otherwise be inaccessible. This initiative plays a crucial role in bridging treatment gaps, giving patients the opportunity to benefit from some of the most advanced therapies available worldwide. 

Note: 

The information provided is for educational purposes only and is subject to prescribing information of the drug and the guidance of your treating physician. Always consult your healthcare provider before making any medical decision for starting your treatment. 

 

References 

  1. FDA Prescribing Information for Lupkynis (Voclosporin) 

  1. https://www.mayoclinic.org/diseases-conditions/lupus-nephritis/diagnosis-treatment/drc-20446438 

  1. https://rheumatology.org/press-releases/new-acr-guideline-summary-provides-guidance-to-screen-treat-and-manage-lupus-nephritis  

  1. Lupkynis Official Website - Safety and Administration Details 

Labels:

Comments

Post a Comment

Popular posts from this blog

Living with Lupus: Understanding SLE and the Role of Benlysta

  Systemic lupus erythematosus (SLE), commonly called lupus, is a long-term autoimmune disease where the body’s immune system—meant to protect against infections—starts attacking its own healthy cells and tissues, causing widespread inflammation and damage. 1   This inflammation can affect various parts of the body including the skin, joints, blood vessels, kidneys, brain, heart, and lungs. 1     What m akes l upus so complicated ?   The disease presents differently in each individual , with variations in symptom type, combination, and severity. Typically, lupus follows a pattern, with episodes of symptom flare-ups alternating with periods of remission when symptoms lessen or temporarily resolve. 1   Common Symptoms of SLE   Symptoms of lupus typically appear gradually, with one or two signs emerging initially and additional or varied symptoms developing over time. Some of the most common ones include 1 :   Joint pain or swelling   Muscl...
Post a Comment
Read more

Foscavir in Resistant Herpesvirus Infections: When to Use It

Introduction Foscavir   is an antiviral medicine used for treating infections caused by certain viruses, especially in people whose immune systems are weak or compromised. It becomes particularly important in cases where standard antiviral treatments fail or when viruses become resistant. Because of its potency and specific uses,  Foscavir   is given under close medical supervision and plays a significant role in managing resistant or severe viral  infections.¹ Understanding Herpesvirus Infections in Immunocompromised Patients  When treatments like cytolytic and cytotoxic drugs weaken the body's  defenses , even normal resident microbes of the skin, gut, and environment, along with viruses already latent in the body such as the human herpesviruses, can become highly pathogenic. This shift increases the number of patients experiencing exaggerated herpetic infections that may become life threatening.  2   Early recognition of infection, rapid and sp...
Post a Comment
Read more

Foscavir Mechanism of Action: How It Inhibits Viral DNA Polymerase

  Introduction: Role of antivirals in CMV and HSV infections   Herpes simplex virus (HSV) and cytomegalovirus (CMV) infections are commonly seen in immunocompromised patients, particularly in patients with HIV. However, fulminant CMV infection and concurrent infection with HSV and CMV in non-HIV patients are quite rare. 1 CMV can lead to severe retinitis and end-organ disease, especially in people with AIDS, 2 HSV can produce stubborn mucocutaneous lesions and infections. 3 CMV and HSV infection can occur simultaneously at distinct sites in the body, and CMV infection may predispose to HSV reactivation due to its long-term effect on cell-mediated immunity. Early recognition of opportunistic infections in immunocompromised patients can affect length of hospital stay, morbidity, and, ultimately, mortality. 1 Antiviral drugs inhibit CMV replication by interfering with viral DNA synthesis. 4 Oral antiviral medications have been shown to decrease the severity of symptoms, red...
Post a Comment
Read more